. Shira Dinner, in her role as Executive Officer for the Alliance for Clinical Trials in Oncology (Alliance) and the Alliance Foundation Trials, LLC (AFT), will expend 40% effort on this project for the next budget period covered from 3/1/18 - 2/28/19. She will oversee the development of protocols for Leukemia, Lymphoma, Myeloma and Transplant; perform operational review on concepts; collaborate with and assist protocol coordinators with protocol development realting to eligibility, testing, observation, schedule and treatment plan and dose modifications. She will review protocols, consents and correspondence about protocols prior to NCI submissions; participate in relevant committee, governmental agency, pharmaceutical partner and research-partner teleconferences. Dr. Dinner will work with protocol budgets, including determining costs for standar of care, reasonable reimbursement for research-releated procedures and drafting budgets for requests from industry or Foundation partners, as well as BIQSFP. She will assit with adverse event review for protocols from assigned committees. Dr. Dinner will manage and triage eleigibility/treatment/dose modificaiton questions on protocols in the absence of study chair. She will also share in the responsibilities for covering emergency unblinding pager.
|Effective start/end date
|4/4/19 → 2/28/25
- Brigham and Women’s Hospital (120870 // 5U10CA180821-10)
- National Cancer Institute (120870 // 5U10CA180821-10)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.